Background and objectives The local prevalence of HPgV-1 has been reported from different countries worldwide, but the global prevalence of HPgV-1 remains unknown. The aim of this systematic review and meta-analysis was to gather data from the literature to estimate the prevalence of HPgV-1 in healthy volunteer blood donors in the world.
Materials and methodsWe searched PubMed, EMBASE, Scopus and Google Scholar databases for records up to January 2019 and included studies reporting HPgV-1 virus prevalence amongst healthy volunteer blood donors based on the detection of HPgV-1 RNA.Results In all, we included 79 studies for the systematic review and 63 for the meta-analysis. Based on the random effect meta-analysis of 35 468 volunteer blood donors, we found the global prevalence of HPgV-1 to be 3Á1% (95% CI, 2Á4-4Á1). The pooled prevalences of HPgV-1 were 1Á7% (95% CI, 1Á1-2Á6) in North America, 9Á1% (95% CI, 6Á4-12Á7) in South America, 2Á3% (95% CI, 2%, 2Á8) in Europe and 2Á4% (95% CI, 1Á4-4) in Asia. Subgroup analyses based on age, gender or risk factors were not possible.Conclusion Approximately 3 in 100 blood donations worldwide are positive for HPgV-1 increasing the risk of infection from transfusion of their components to subsequent recipients. Further research on virus pathogenicity is required before recommending routine screening of HPgV-1 for healthy volunteer blood donors.